DKK1 作为骨髓瘤免疫治疗的新靶点。
DKK1 as a novel target for myeloma immunotherapy.
机构信息
Department of Lymphoma/Myeloma; Division of Cancer Medicine; Center for Cancer Immunology Research; The University of Texas MD Anderson Cancer Center; Houston, TX USA.
出版信息
Oncoimmunology. 2012 Aug 1;1(5):756-758. doi: 10.4161/onci.19655.
Abstract
Novel, potent tumor-associated antigens are needed to improve the efficacy of immunotherapy for myeloma. We demonstrated that active vaccination using the DKK1-DNA vaccine in the myeloma mouse model protected mice from developing myeloma and effectively treated established myeloma. Therefore, DKK1 could be developed as a novel vaccine for myeloma immunotherapy.
摘要
需要新型、强效的肿瘤相关抗原来提高骨髓瘤免疫治疗的疗效。我们证明，在骨髓瘤小鼠模型中使用 DKK1-DNA 疫苗进行主动免疫接种可以保护小鼠免于发生骨髓瘤，并有效治疗已建立的骨髓瘤。因此，DKK1 可被开发为骨髓瘤免疫治疗的一种新型疫苗。
Zotero 插件